The Board Of Trustees

Spenden & Helfen

The Board Of Trustees

Peter Breuer, chairman of the board of trustees, is the first son of the founder, Hans Breuer, and his wife, Ilse Breuer, and was born in 1948 in Neu-Isenburg. He is married and has one child. Peter Breuer is an independent businessman.

Roland Bergfeld (LL.M.) is admitted attorney in Germany and New York. Born 1971 in Frankfurt, he gradutated at Heidelberg Universtity and Northwestern University. Later he gained extensive experience in consulting various foundations.

Stefan Breuer was born in 1957 in Neu Isenburg, he is the second son of Hans and Ilse Breuer. He is married and has five children. Stefan Breuer currently lives and works in Switzerland, as an independent businessman.

Prof. Dr. rer. nat. Dr. h.c. Christian Haass was born in 1960. He studied biology at the University of Heidelberg, where he received his doctorate in 1989. He then went to Harvard Medical School and was appointed Assistant Professor of Neurology in 1992. From 1995 he was head of the Department of Molecular Biology at the Central Institute of Mental Health (ZI) in Mannheim. In 1999, he was appointed Professor of Metabolic Biochemistry at the LMU Munich and head of the Adolf-Butenandt Institute. In the same year, Prof. Haass initiated the first Germany-wide research network on Alzheimer's disease with the foundation of the DFG research focus "Cellular Mechanisms of Alzheimer's Disease". In 2000 he was spokesman for the DFG Collaborative Research Center "Molecular Mechanisms of Neurodegeneration". Christian Haass has been honored with numerous awards, including the "International Alois Alzheimer Award", the "Gottfried Wilhelm Leibniz" Prize of the DFG, the "Ernst Jung Prize for Medicine", the "Potamkin" Prize of the American Academy of Neurology and received the honorary doctorate of the University of Zurich. In January 2014, he received the Federal Cross of Merit on ribbon. His work is now an essential foundation for therapeutic approaches in Alzheimer's disease. His research focuses on the molecular biology of Alzheimer's and Parkinson's disease.

Andreas C. Hübner is Senior Managing Director of Lazard Asset Management LLC and is responsible for the business activities of Lazard Asset Management (Deutschland) GmbH with offices in Frankfurt, Hamburg, Milan, Zurich and Geneva. He has been in investment management since 1984. Prior to joining Lazard in 1999, Mr. Hübner was a personally liable partner of SMH Schröder Münchmeyer Hengst & Co., a German private bank, active in both investment banking and asset management. Mr. Hübner previously worked at UBS Asset Management and DG Bank in New York and Frankfurt. Mr. Hübner is fluent in German and English and has his office in Frankfurt.
He is a member of the Lions Club Frankfurt Eschenheimer Tor, Club of Finance, participant of the BBUG class 105, member of the Städelkomittee Frankfurt, member of the MMK Tischgesellschaft and member of the Atlantikbrücke e.V., Berlin and the Museumsgesellschaft Frankfurt as well as chairman of the Patrons Association of the Städtische Bühnen Frankfurt e.V.

Prof. Dr. Wolfgang Hoffmann, MPH, was born in 1963 in Cologne. He heads the Department of Nursing Epidemiology and Community Health of the Institute for Community Medicine at the University Medical Center Greifswald. Prof. Hoffmann is a long-time board member of the German Society for Epidemiology (DGEpi) and a member of the Epidemiological Planning Committee as well as one of the four speakers of the National Cohort. In addition, he was elected to the board of the Technology and Methodology Platform for Networked Medical Research (TMF) of the Federal Ministry of Education and Research (BMBF) and is also a member of the executive board and a member of the commission "Health Reporting and Health Monitoring" of the Robert Koch- Institute (RKI), Berlin. Since January 2013 he has been speaker and head of the German Center for Neurodegenerative Diseases (DZNE) in Rostock / Greifswald.
The research focus of Prof. Hoffmann is the development of evidence-based, sustainable, cost-effective treatment pathways for the health and quality of life of people with dementia and their relatives as well as their implementation in the health care system.